Coegin Pharma will participate in the following events:
Coegin Pharma does not have any upcoming events at the moment.
Avexxin has several molecules in the pipeline at different developmental stages, targeting the group IVA cPLA2 enzyme. The newest molecules were added to the portfolio in 2015.
All of Avexxin’s small molecules are nanomolar potent drug candidates targeting chronic inflammatory disorders and cancers with high unmet need. The individual compounds represent a series of international drug discovery efforts conducted in collaboration with key leaders in the field
With our lead compound – AVX001 – we are developing a novel therapy for the treatment of psoriasis and other skin conditions. The mechanism based, rationally designed, lead compound is a potent inhibitor of TNFa induced inflammation in keratinocytes, and a potent candidate for a powerful anti-psoriatic drug.
Coegin Pharma is a global leader in understanding the role of an intracellular target downstream of the classical therapeutic intervention of the pro-inflammatory cascade activated by NFkB. Coegin Pharma’s small molecules inhibits the group IVA cPLA2 enzyme, however still allowing the cell to function at the physiological level.
It is the company’s strategy to partner its compounds at an appropriate stage in development. For further information about our partnering strategy, please contact Mikael Oerum, CEO.
Avexxin presents the newest paper published in a scientific journal with the title “A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis.”, published in Journal of the European Academy of Dermatology and Venereology, January 2017.
Read the full article here